B+
Bull case
30%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
NVCR
NovoCureFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The constructive case is that Novocure now has multiple concrete proof points rather than a pure platform story: Japan reimbursement approval for Optune Lua opens a new covered market for NSCLC [#PR-2026-03-02], PANOVA-4 reported statistically significant disease-control improvement in metastatic pancreatic cancer [#PR-2026-03-26], and management's 2026 guide implies incremental contribution from newer indications and products [#PR-2026-02-26-FY]. With the stock still near $12.67 versus a packet median target near $25.93, the setup can work if upcoming milestones convert into visible patient and revenue traction.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
April 30, 2026 earnings could fail to show convincing early revenue contribution from Optune Pax and Optune Lua.
Momentum
22
Value
36
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.50 · Bull $19.00 · Bear $8.50Analysis 2026-04-21; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $26.86
Why
Momentum22 · Δ7d -1.5
Value36 · Δ7d +0.0
Sentiment47 · Δ7d -3.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29 · BMO.
- • Sentiment remains the lead driver in the composite, 7D delta -3.5.
Contradictions & invalidation
- • April 30, 2026 earnings could fail to show convincing early revenue contribution from Optune Pax and Optune Lua.
- • Clinical readout risk remains high around TRIDENT despite management's Q2 2026 timing.
- • The bearish case is that forward visibility is still limited and the thesis remains milestone-dependent.
Catalyst clock
2026-10-29 · BMO
Q1 2026 results on April 30 can validate early Optune Pax/Lua revenue ramp and active-patient trajectory
Lead driver: Sentiment · See AI snapshot
Momentum
22
8% active weight
Current posture
7d trendFlat
Δ7d
-1.5
Δ21d
-16.6
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.5
Δ21d
-6.6
Why this grade
Composite grade F. Momentum 21.8 / Value 36.3 / Sentiment 46.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.71B
Beta
0.72
Shares Out
116.45M
P/E (TTM) · Derived
-12.0
P/S (TTM)
2.40
P/FCF (TTM) · Derived
-65.59
Rev YoY
+15.6%
EPS YoY
-62.5%
Gross Margin
+76.1%
Op Margin
-22.1%
Net Debt
-$209.16M
Current Ratio
2.89
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data